Patents by Inventor Celia M. Sharp

Celia M. Sharp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, asparate 101 or leucine 137
    Patent number: 7138374
    Abstract: The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: November 21, 2006
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, Aspartate 101 or Leucine 137
    Patent number: 6767722
    Abstract: The present invention relates to muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed is a method for stimulating cell division.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: July 27, 2004
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137
    Patent number: 6737404
    Abstract: The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: May 18, 2004
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Analogs of human basic fibroblast growth factor
    Publication number: 20010020004
    Abstract: The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.
    Type: Application
    Filed: April 5, 2001
    Publication date: September 6, 2001
    Applicant: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
    Patent number: 6274712
    Abstract: The present invention relates to muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of the nucleic acid sequences and the production of the muteins.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: August 14, 2001
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Apparatus and method preventing radiation induced degradation of optical elements
    Patent number: 4641033
    Abstract: An apparatus and method for maintaining an optical element at a sufficiently high temperature during transmission of radiation by the optical element to prevent radiation degradation of the optical element by an increase in the absorption of at least one wavelength of the radiation. The material of the optical element is such that the absorption of the wavelength(s) concerned temporarily decreases upon annealing the optical element. The optical element may be kept at the temperature required by a wide variety of heating techniques, including gas convection heating, direct contact heating, and radiant heating. The heated optical element may be employed in optical systems for transmitting radiation from a source of radiation to a target to be exposed to this radiation.
    Type: Grant
    Filed: December 19, 1984
    Date of Patent: February 3, 1987
    Assignee: Fusion Systems Corporation
    Inventors: Andrei N. Petelin, Celia M. Sharp, Michael G. Ury, Gene R. Wooden